Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ibritumomab Tiuxetan (Zevalin®) in Patients With Previously Untreated Marginal Zone Lymphoma

NCT00453102 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT00453102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00453102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ibritumomab Tiuxetan (Zevalin®) in Patients With Previously Untreated Marginal Zone Lymphoma
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
February 28, 2015
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma